FDA grants traditional approval to Novartis’ Fabhalta for IgAN
The US Food and Drug Administration (FDA) has issued traditional approval to Novartis for Fabhalta (iptacopan), to slow…
Novartis Fabhalta® (iptacopan) receives FDA traditional approval as first and only complement inhibitor to significantly slow kidney function decline in primary IgAN
Fabhalta slowed eGFR decline by 48% vs placebo over two years, demonstrating kidney function preservation1 Clinically meaningful improvements of…
Novartis reports positive results from Phase III ALIGN trial for IgAN
Novartis has announced final results from the Phase III ALIGN study, highlighting that Vanrafia (atrasentan) slows kidney function…
Novartis AG (NVS) Announces Final Two-Year Results From Phase III APPLAUSE‑IgAN Study
Novartis AG (NYSE:NVS) is one of the best pharma stocks to invest in now. Novartis AG (NYSE:NVS) announced on…
Novartis IgAN data in New England Journal of Medicine show Fabhalta® slowed kidney function decline by 49.3%
– Novartis today announced final two-year results from the Phase III APPLAUSE‑IgAN study of Fabhalta® (iptacopan) in IgA…
Novartis reports final data of ALIGN trial in IgAN
Novartis has announced final data from the Phase III ALIGN study, highlighting that Vanrafia (atrasentan) slowed kidney function…